Patents Assigned to Chiron
  • Polynucleotides that hybridize to DP-75 and their use
    Patent number: 7329741
    Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecules, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 12, 2008
    Assignee: Chiron Corporation
    Inventor: David Duhl
  • Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
    Patent number: 7326711
    Abstract: Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: February 5, 2008
    Assignee: Chiron Corporation
    Inventors: Weibo Wang, Ryan N. Constantine, Liana Marie Lagniton, Sabina Pecchi, Matthew T. Burger, Manoj C. Desai
  • Hepatitis C virus E2 binding protein
    Patent number: 7320875
    Abstract: HCV assays are described. The assays utilize a 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), or functionally equivalent variants or fragments of the 24 kd protein.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: January 22, 2008
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Publication number: 20070299039
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: November 18, 2005
    Publication date: December 27, 2007
    Applicant: Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Leonard Sung
  • Novel Splice Variants of Human Dkkl1
    Publication number: 20070282015
    Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice forms of human DKKL 1 gene. The present invention provides methods of using polynucleotides having the novel splice variants of the human DKKL 1 sequences, their corresponding gene products and antibodies specific for the gene products in the detection, diagnosis, prevention and/or treatment of associated cancers.
    Type: Application
    Filed: September 30, 2004
    Publication date: December 6, 2007
    Applicant: CHIRON CORPORATION
    Inventor: Lai Albert
  • Method for cyrstallizing human GSK3 and novel crystal structure thereof
    Publication number: 20070264699
    Abstract: The invention provides the three-dimensional structure of a construct of human glycogen synthase kinase 3 (GSK3); crystals of a construct of human glycogen synthase kinase 3-? (GSK3-?) containing the protein's catalytic kinase domain; a method for crystallizing the protein construct to provide a GSK3 crystal sufficient for structure determination; and a method for using the GSK3 construct's three-dimensional structure for the identification of possible therapeutic compounds in the treatment of various disease conditions mediated by GSK3 activity.
    Type: Application
    Filed: June 29, 2007
    Publication date: November 15, 2007
    Applicant: Chiron Corporation
    Inventors: Dirksen Bussiere, Vincent Le
  • Sos1 inhibitors
    Patent number: 7291725
    Abstract: Inhibitors of human Sos1, including antisense oligonucleotides, methods, and compositions specific for human Sos1, are provided. Methods of using the compositions for modulating Sos1 expression and for regulating cell growth, particularly tumor cell growth, are also provided.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: November 6, 2007
    Assignee: Chiron Corporation
    Inventors: Birgit K. Jaitner, Wendy J. Fantl
  • Immunogenic detoxified mutant LT-A toxin
    Patent number: 7291588
    Abstract: An immunogenic detoxified protein is provided which comprises the amino acid sequence of subunit A of an E. coli heat labile toxin (LT-A) or a fragment thereof in which at least amino acid Ala-72 of the A subunits mutated, preferably by substitution with Arg. The toxoid is useful as vaccine against an enterotoxigenic strain of E. coli and is produced by recombinant DNA means by site-directed mutagenesis. It is also an effective adjuvant.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: November 6, 2007
    Assignee: Chiron Srl
    Inventors: Mariagrazia Pizza, Marzia Monica Giuliani, Rino Rappuoli
  • GSK3 polypeptides
    Publication number: 20070249004
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Application
    Filed: February 8, 2007
    Publication date: October 25, 2007
    Applicant: Chiron Corporation
    Inventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
  • Activation of HCV-specific T cells
    Patent number: 7285539
    Abstract: The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: October 23, 2007
    Assignee: Chiron Corporation
    Inventors: Xavier Paliard, Michael Houghton, Mark Selby
  • Metastatic breast and colon cancer regulated genes
    Patent number: 7279307
    Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: October 9, 2007
    Assignee: Chiron Corporation
    Inventors: Klaus Giese, Hong Xin
  • Notch receptor ligands and uses thereof
    Patent number: 7279554
    Abstract: The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: October 9, 2007
    Assignee: Chiron Corporation
    Inventors: Vivien Chan, Michael Rohan, Lewis T. Williams
  • USE OF A PROMOTER OF T-CELL EXPANSION AND AN INDUCER OF CD40 STIMULATION IN THE TREATMENT OR PREVENTION OF A PATHOLOGIC STATE
    Publication number: 20070231299
    Abstract: The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system.
    Type: Application
    Filed: December 11, 2006
    Publication date: October 4, 2007
    Applicants: and Hu, University of Minnesota, Chiron Corporation
    Inventors: William Murphy, Robert Wiltrout, Bruce Blazar, Susan Wilson
  • Antibodies to EGFH2 polypeptides
    Patent number: 7276587
    Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: October 2, 2007
    Assignee: Chiron Corporation
    Inventors: W. Michael Kavanaugh, Hui Cen, Pauline Lee
  • Method for administering agents to the central nervous system
    Patent number: 7273618
    Abstract: The present invention is directed to a method for delivering agents to the central nervous system by way of a tissue innervated by the trigeminal nerve that is outside the nasal cavity. Such a method of delivery can be useful in the treatment of central nervous system and/or brain disorders.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: September 25, 2007
    Assignee: Chiron Corporation
    Inventors: William H. Frey, II, Robert Gary Thorne
  • Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
    Publication number: 20070218060
    Abstract: Methods of therapy for treating a subject for multiple myeloma are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing multiple myeloma cells.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 20, 2007
    Applicant: Chiron Corporation
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror
  • KGF polypeptide compositions
    Patent number: 7265089
    Abstract: Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163. Accordingly, the KGF polypeptides of the present invention may be used in compositions in lesser amounts than would be necessary using KGF163.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: September 4, 2007
    Assignee: Chiron Corporation
    Inventors: Denis J. Gospodarowicz, W. Michael Kavanaugh, Kenneth Crawford
  • Compositions providing for increased IGF-I solubility
    Patent number: 7262168
    Abstract: Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: August 28, 2007
    Assignee: Chiron Corporation
    Inventors: Bret A. Shirley, Kamaljit Bajwa
  • Essential and important genes of Pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents
    Publication number: 20070196829
    Abstract: The invention includes a database of candidate essential genes in Pseudomonas aeruginosa, as well as other important genes that, when mutated, lead to a growth attenuated phenotype. Such genes and mutants of such genes are important for identifying antibacterial agents suitable for treating and preventing Pseudomonas aeruginosa infections. The invention includes methods for confirming the essentiality or importance of candidate genes, as well as methods for utilizing those genes to screen for new antibacterial drugs. The invention also includes the antibacterial agents identified using the disclosed methods, as well as methods of using the same for treating and preventing Pseudomonas infection.
    Type: Application
    Filed: October 11, 2005
    Publication date: August 23, 2007
    Applicant: CHIRON CORPORATION
    Inventors: Kim Bruce, Paul Warrener, Kevin Hou
  • Human FGF-21 polypeptides
    Patent number: 7259248
    Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: August 21, 2007
    Assignees: Chiron Corporation, Kyoto University
    Inventors: Nobuyuki Itoh, W Michael Kavanaugh